Patients with Unresectable Stage IIIA/B EGFR-Positive NSCLC
Conditions
Interventions
Treatment group:Third-generation EGFR TKIs will be administered for 3-6 months, during which the timing and protocol for concurrent radiotherapy will be determined ba
Sponsors
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients with histologically or cytologically confirmed AJCC TNM Stage IIIA/B (8th edition) unresectable EGFR-positive NSCLC, including histopathological subtypes such as lung adenocarcinoma and lung squamous cell carcinoma. 2.No prior first-line systemic anti-tumor therapy for advanced NSCLC; 3.Physical condition and organ function allow for systemic anti-tumor therapy, including radiotherapy and targeted therapy; 4.Age =18 years at the time of signing the informed consent form; 5.Availability of molecular pathology test results from blood samples and/or tumor tissue samples before the initiation of first-line treatment; 6.Ability to adhere to the planned schedule and actively cooperate with regular clinical follow-up and necessary treatment. 7.Willingness to provide the required clinical data for the study and consent to the use of test data for further scientific research and commercial product development.
Exclusion criteria
Exclusion criteria: 1.Patients with any other active malignancy within the 5 years prior to enrollment. Patients with cured localized tumors such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, in situ prostate cancer, in situ cervical cancer, and in situ breast cancer are eligible for enrollment; 2.Patients who have previously received systemic anti-tumor therapy for advanced NSCLC but do not have genetic testing results before the start of treatment; 3.Patients with other serious diseases that may affect follow-up and/or significantly shorten survival, as determined by the investigator. 4.Patients with any other conditions or social/psychological issues that the investigator deems unsuitable for participation in this study. 5.Patients who cannot undergo clinical follow-up using contrast-enhanced magnetic resonance imaging (MRI) or contrast-enhanced computed tomography (CT).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2 year PFS ratio; | — |
Countries
China
Contacts
Public ContactXiang Yi/Zhao Shengguang
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed